MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Formula:C28H29FN6O2Color and Shape:SolidMolecular weight:500.57Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Formula:C26H34F3N5O3Purity:98.36% - 99.84%Color and Shape:SolidMolecular weight:521.58Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Formula:C16H21ClN2O4SPurity:99.75%Color and Shape:SolidMolecular weight:372.87HG6-64-1
CAS:<p>HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.</p>Formula:C32H34F3N5O2Purity:99.89%Color and Shape:SolidMolecular weight:577.64ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Formula:C26H30N4O2SPurity:99.70%Color and Shape:SolidMolecular weight:462.61JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Formula:C34H44N8O3Purity:98.33%Color and Shape:SolidMolecular weight:612.77BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Formula:C24H27N7OSPurity:97.74% - 99.88%Color and Shape:SoildMolecular weight:461.58Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Formula:C36H41Cl2F3N6O2Purity:99.77%Color and Shape:SolidMolecular weight:717.65MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Formula:C31H34N8O2Color and Shape:SolidMolecular weight:550.65MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Formula:C29H39N5O6S2Color and Shape:SolidMolecular weight:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Formula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74
